AR046086A1 - Derivados de 1,3- benzoxazolilo como inhibidores de quinasa - Google Patents
Derivados de 1,3- benzoxazolilo como inhibidores de quinasaInfo
- Publication number
- AR046086A1 AR046086A1 ARP040103452A ARP040103452A AR046086A1 AR 046086 A1 AR046086 A1 AR 046086A1 AR P040103452 A ARP040103452 A AR P040103452A AR P040103452 A ARP040103452 A AR P040103452A AR 046086 A1 AR046086 A1 AR 046086A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- atoms
- mono
- scf3
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El presente se refiere a su composición y uso para el tratamiento de enfermedades, en especial tumores y/o enfermedades que son causadas, mediadas y/o propagadas por angiogénesis. Los compuesos de la fórmula (1) son inhibidores eficaces de las tirosina quinasas, en particular TIE-2 y VEGFR, y de las Raf-quinasas. Reivindicación 1: Compuestos de la fórmula (1), en donde significan: R1, R2, R3 en cada caso, de modo independiente entre sí, R, Hal, CN, NO2, NHR, NRR, NHCOR, NHSO2R, OR, CO-R, CO-NHR, CF3, OCF3, SCF3, SO3R, SO2R, SO2NR, SR, COOH o COOR; R es H o A, AR, Het, (CH2)qHet o (CH2)qAr insustituido o mono, di, tri o tetrasustituido con R4; a es alquilo no ramificado, ramificado o cíclico C1-14, en donde uno o dos grupos CH2 pueden estar reemplazados por átomos de O o S y/o por grupos -CH=CH- y/o también 1-7 átomos de H pueden estar reemplazados por F y/o Cl; Ar es fenilo, naftilo o bifenilo insustituido o mono, di o trisustituido con A, Hal, OH, OA, CN, NO2, NH2, NHA, NA2, NHCOA, SCF3, SO2A, CO-OH,COOA, CONH2, CONHA, CONA2, NHSO2A, SO2NH2, SO2NHA, SO2NA2, CHO o COA; Het es un heterociclo mono o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar insustituido o mono, di o trisustituido con el oxígeno del carbonilo, Hal, A, -(CH2)b-Ar, -(CH2)b-cicloalquilo, OH, OA, NH2, NHA, NA2, NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2 y/o S(O)gA; Hal es F, Cl, Br o I; R4 es Hal, OH, CN, NO2, CF3, OCF3, SCF3, SO2A, u OA; X es O, S,SO2NH o NH; el circulo Y es fenilo o un heterociclo aromático monocíclico con 1 a 4 átomos de N, O y/o S; b es 0, 1, 2, 3 o 4; g es 0, 1 o 2; n, m, p, q son en cada caso, de modo independiente entre sí, 1, 2, 3 ó 4; así como sus sales, derivados, solvatos y estereoisómeros farmacéuticamente inocuos, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344223A DE10344223A1 (de) | 2003-09-24 | 2003-09-24 | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046086A1 true AR046086A1 (es) | 2005-11-23 |
Family
ID=34353052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103452A AR046086A1 (es) | 2003-09-24 | 2004-09-24 | Derivados de 1,3- benzoxazolilo como inhibidores de quinasa |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8242128B2 (es) |
| EP (1) | EP1664039B1 (es) |
| JP (1) | JP5103013B2 (es) |
| AR (1) | AR046086A1 (es) |
| AU (1) | AU2004281879B2 (es) |
| CA (1) | CA2539767C (es) |
| DE (1) | DE10344223A1 (es) |
| WO (1) | WO2005037829A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| PT1636585E (pt) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
| US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| US7517995B2 (en) | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| EP1900729A1 (en) | 2006-09-15 | 2008-03-19 | Novartis AG | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| TW200940539A (en) * | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
| KR20100122505A (ko) * | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Ｒａｆ 저해물질 화합물 및 이들의 이용 방법 |
| WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| CA2803118C (en) | 2010-07-09 | 2015-11-03 | Pfizer Limited | Sulfonamide derivatives as nav 1.7 inhibitors |
| WO2015066241A1 (en) * | 2013-10-30 | 2015-05-07 | Novartis Ag | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
| MX2020004202A (es) | 2017-10-30 | 2020-08-13 | Neuropore Therapies Inc | Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. |
| KR20240043869A (ko) * | 2022-09-27 | 2024-04-04 | 이화여자대학교 산학협력단 | 4-아미노-부탄아미드를 포함하는 신규한 벤조옥사졸 유도체 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579857B1 (en) * | 1999-06-11 | 2003-06-17 | Evanston Northwestern Healthcare Research Institute | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| SG148834A1 (en) * | 1999-06-30 | 2009-01-29 | Japan Tobacco Inc | Compounds for the modulation of ppary activity |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| EP1330432A2 (en) * | 2000-11-04 | 2003-07-30 | Aventis Pharma Limited | Substituted alkanoic acids |
| WO2002044156A2 (en) * | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| GB0102687D0 (en) * | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| US20030009034A1 (en) * | 2001-03-22 | 2003-01-09 | Neil Wishart | Transition metal mediated process |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| JP2005524609A (ja) * | 2001-12-17 | 2005-08-18 | スミスクライン ビーチャム コーポレーション | ピラゾロピリダジン誘導体 |
| CA2480638C (en) * | 2002-03-29 | 2013-02-12 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
| US20030225131A1 (en) * | 2002-04-05 | 2003-12-04 | Burgey Christopher S. | Thrombin inhibitors |
| DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
-
2003
- 2003-09-24 DE DE10344223A patent/DE10344223A1/de not_active Withdrawn
-
2004
- 2004-09-01 CA CA2539767A patent/CA2539767C/en not_active Expired - Fee Related
- 2004-09-01 JP JP2006527292A patent/JP5103013B2/ja not_active Expired - Fee Related
- 2004-09-01 WO PCT/EP2004/009743 patent/WO2005037829A1/de active Application Filing
- 2004-09-01 US US10/573,176 patent/US8242128B2/en not_active Expired - Fee Related
- 2004-09-01 AU AU2004281879A patent/AU2004281879B2/en not_active Ceased
- 2004-09-01 EP EP04764704.5A patent/EP1664039B1/de not_active Not-in-force
- 2004-09-24 AR ARP040103452A patent/AR046086A1/es unknown
-
2012
- 2012-05-08 US US13/466,464 patent/US20120220611A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5103013B2 (ja) | 2012-12-19 |
| US20060281762A1 (en) | 2006-12-14 |
| AU2004281879B2 (en) | 2011-04-07 |
| JP2007506687A (ja) | 2007-03-22 |
| US20120220611A1 (en) | 2012-08-30 |
| EP1664039B1 (de) | 2014-03-05 |
| US8242128B2 (en) | 2012-08-14 |
| CA2539767C (en) | 2013-02-05 |
| DE10344223A1 (de) | 2005-04-21 |
| CA2539767A1 (en) | 2005-04-28 |
| AU2004281879A1 (en) | 2005-04-28 |
| EP1664039A1 (de) | 2006-06-07 |
| WO2005037829A1 (de) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046086A1 (es) | Derivados de 1,3- benzoxazolilo como inhibidores de quinasa | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR045626A1 (es) | Derivados del bencil- bencimidazolilo | |
| AR046140A1 (es) | Derivados de bencimidazolilo, procedimiento de preparacion y usos | |
| AR046748A1 (es) | Derivados de amina que inhiben,regulan,y/o modulan tirosinaquinasas,composiciones farmaceuticas que los contienen,procedimientos de preparacion y compuestos intermediarios | |
| AR051623A1 (es) | Derivados de piridopirimidinona | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR080803A1 (es) | Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias. | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR053569A1 (es) | Derivados de pirazol | |
| PE20021010A1 (es) | Derivados espirociclicos como inhibidores de fosfodiesterasa-7 | |
| DOP2002000482A (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
| AR054047A1 (es) | Derivados de fenilquinazolina | |
| GT200600398A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
| AR082728A1 (es) | Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR055376A1 (es) | Derivados de 1-acildihidropirazol | |
| AR028914A1 (es) | 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 | |
| AR056310A1 (es) | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |